Etiology

  • Premature birth
  • Maternal diabetes mellitus: leads to ↑ fetal insulin, which inhibits surfactant synthesis
  • Hereditary
  • Cesarean delivery: results in lower levels of fetal glucocorticoids than vaginal delivery, in which higher levels are released as a response to stress from uterine contractions
  • Hydrops fetalis
  • Multifetal pregnancies
  • Male sex

Pathophysiology

  • Deficiency of pulmonary surfactant in premature infants.
  • Surfactant is produced by Type II pneumocytes starting around 24-28 weeks gestation, with mature levels achieved after 35 weeks.
  • Key component of surfactant: Dipalmitoylphosphatidylcholine (DPPC).
  • Function of surfactant: ↓ alveolar surface tension, which prevents atelectasis at end-expiration.
  • Deficiency → ↑ alveolar surface tension → widespread atelectasis → ↓ lung compliance → V/Q mismatch → hypoxemia & hypercapnia.

Clinical features

  • Maternal history of premature birth
  • Onset of symptoms: usually immediately after birth but can occur up to 72 hours postpartum
  • Signs of increased respiratory effort
    • Tachypnea
    • Nasal flaring and moderate to severe subcostal/intercostal and jugular retractions
  • Characteristic expiratory grunting
  • Decreased breath sounds on auscultation
  • Cyanosis due to pulmonary hypoxic vasoconstriction

Diagnostics


  • X-ray chest
    • Interstitial pulmonary edema with perihilar streaking
    • Diffuse, fine, reticulogranular (ground-glass) densities with low lung volumes and air bronchograms
    • Atelectasis
  • Prenatal Assessment: Lecithin-to-sphingomyelin (L/S) ratio in amniotic fluid.
    • L/S ratio < 2.0 indicates lung immaturity.
    • Presence of phosphatidylglycerol signifies lung maturity.
    • The amount of lecithin, which is the major component of surfactant, starts increasing after week 26 of gestation.
    • The lower the lecithin-sphingomyelin ratio, the more likely it is that the lungs are immature.

Differential diagnostics

Apnea of prematurity

  • Etiology/Pathophysiology
    • Common in preterm infants (<37 weeks gestation) due to immature respiratory control centers.
    • Incidence inversely proportional to gestational age.
    • Types: Central (immature brainstem drive), Obstructive (airway collapse), Mixed (most common).
  • Clinical Features & Diagnostics
    • Defined as respiratory pause >20 seconds OR shorter pause with bradycardia (<100 bpm) or desaturation (<85%).
    • Onset typically 2-3 days post-birth.
    • Diagnosis of exclusion (rule out sepsis, metabolic, CNS, cardiac issues).
    • Car Seat Challenge before discharge.
  • Treatment
    • Tactile stimulation, proper positioning.
    • Pharmacologic: Methylxanthines (e.g., Caffeine citrate - preferred for central stimulation).
    • Respiratory Support: Nasal CPAP (for obstructive/mixed apnea), mechanical ventilation for severe cases.
  • Prognosis
    • Excellent; resolves as infant matures, typically by 40-44 weeks postmenstrual age.

Complications

Bronchopulmonary dysplasia (BPD)

  • Definition: chronic lung condition secondary to prolonged mechanical ventilation and oxygen therapy for NRDS
  • Etiology: Pulmonary barotrauma and oxygen toxicity with subsequent inflammation of lung tissue due to ventilation of the immature lung (ventilation for more than 28 days)
  • Clinical features
    • Seen in infants < 32 weeks
    • Persistence of symptoms similar to NRDS (e.g., tachypnea, grunting, nasal flaring)
    • Episodes of desaturation
  • Diagnostics
    • X-ray chest: diffuse, fine, granular densities, areas of atelectasis interspersed with areas of hyperinflation
    • Blood gas analysis: respiratory and metabolic acidosis
    • Histology: atelectasis, fibrosis, emphysematous alveolar changes (decreased number and septation of alveoli)
  • Treatment: controlled oxygenation, diuretics, rarely glucocorticoids